(6) Segments and Geographic Information

The Company and its subsidiaries currently operate in two segments, product and service. The product segment oversees the supply chain and manufacturing of Crinone, the Company’s sole commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services for the Company’s customers as well as characterizing and developing pharmaceutical product candidates for the Company’s internal programs. The Company conducts its advanced formulation, analytical and consulting services through its subsidiary, Juniper Pharma Services, the Company’s UK-based provider of pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services to the pharmaceuticals industry. The Company has integrated its supply chain management for Crinone into those operations and has therefore sought to capture synergies by transferring all operational activities related to its historic business. The Company owns certain plant and equipment physically located at third-party contractor facilities in the United Kingdom and Switzerland.

The Company’s largest customer, Merck KGaA, utilizes a Switzerland-based subsidiary to acquire product from the Company, which it then sells throughout the world, excluding the United States.

The following tables show selected information by geographic area (in thousands):

Revenues:

	Three Months Ended March 31,
	2018		2017
United States	$	3,542	$	1,628
Switzerland		10,278		7,757
United Kingdom		793		949
Other countries		911		913
Total	$	15,524	$	11,247

Total assets:

	March 31, 2018		December 31, 2017
United States	$	21,233	$	21,683
Switzerland		4,916		1,366
United Kingdom		38,371		38,129
Other countries		19		42
Total	$	64,539	$	61,220

Long-lived assets:

	March 31, 2018		December 31, 2017
United States	$	396	$	523
Switzerland		536		535
United Kingdom		15,717		15,064
Other countries		2		2
Total	$	16,651	$	16,124

Long-lived assets include fixed assets, intangibles and other assets.

No other individual country represented greater than 10% of total revenues, total assets or long-lived assets for any period presented.

For the three months ended March 31, 2018 and 2017, Merck KGaA accounted for 100% of the product segment revenue. At March 31, 2018 and December 31, 2017, Merck KGaA made up 100% of the product segment accounts receivable.

For the three months ended March 31, 2018 and 2017, the same customer accounted for 33% and 17% of the service segment total revenue, respectively. No additional customers accounted for 10% or more of the service segment total revenue for the three months ended March 31, 2018 and 2017. At March 31, 2018 and December 31, 2017, one customer accounted for 44% and 53% of total service segment accounts receivable, respectively.

The following summarizes other information by segment for the three months ended March 31, 2018 (in thousands):

	Product		Service		Total
Revenues
Product revenues	$	10,074	$	—	$	10,074
Service revenues		—		5,450		5,450
Total revenues	$	10,074	$	5,450	$	15,524
Cost of product revenues	$	6,016	$	—	$	6,016
Cost of service revenues		—		3,010		3,010
Total cost of revenues	$	6,016	$	3,010	$	9,026
Gross profit	$	4,058	$	2,440	$	6,498
Total operating expenses						5,482
Total non-operating expense						(244	)
Income (loss) before income taxes					$	772

The following summarizes other information by segment for the three months ended March 31, 2017 (in thousands):

	Product		Service		Total
Revenues
Product revenues	$	7,726	$	—	$	7,726
Service revenues		—		3,521		3,521
Total revenues	$	7,726	$	3,521	$	11,247
Cost of product revenues	$	4,313	$	—	$	4,313
Cost of service revenues		—		2,243		2,243
Total cost of revenues	$	4,313	$	2,243	$	6,556
Gross profit	$	3,413	$	1,278	$	4,691
Total operating expenses						6,146
Total non-operating income						14
Income (loss) before income taxes					$	(1,441	)